NEW YORK, Nov. 6 – Invitrogen is exploring the possibility of acquiring Incyte Genomics, a source inside Invitrogen told GenomeWeb.    

The source, a senior-level employee who asked not to be named, said that the company is interested in acquiring the genomics data provider but is waiting to act until the price is right.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.